The Biotech Sector Swings Between Breakthroughs and Setbacks

A delisting, an FDA ban, a $115 million convertible bond issue, and a psychedelics spin: The news surrounding five pharmaceutical and biotech stocks this week could hardly be more diverse.

While Redcare Pharmacy shines with strong quarterly results, Sangamo Therapeutics is fighting for survival. A look at the sector reveals just how closely euphoria and disillusionment can be intertwined.

Biotech Company Redcare Pharmacy: EBITDA jump makes a statement

Redcare Pharmacy presented strong first-quarter results on Wednesday. Revenue grew by 18.4% year-on-year, and adjusted EBITDA jumped by a substantial 58% to €14.4 million. The prescription drug business in Germany was a key driver of this growth, with Rx sales increasing by 55%. The over-the-counter segment also showed a significant recovery – from 5% growth in the fourth quarter of 2025 to 9% in the first quarter, and even reaching around 11% in April.

Management has confirmed its annual forecast: 13 to 15% revenue growth, prescription drug sales in Germany exceeding €670 million, and an adjusted EBITDA margin of at least 2.5%. A 67% market share in the German online prescription market gives the company a dominant position.

It won’t be easy, though. Drugstore chain dm has launched its own online pharmacy, “dm-med,” and Rossmann is working on a similar project. Jefferies is nevertheless maintaining its price target of €150, and Deutsche Bank also recommends buying. The stock is currently trading at €48.42—an increase of 4.58% on Thursday, but still almost 28% below its level at the start of the year. Margin development remains the crucial indicator for the coming quarters.

Ocugen: Sales surprise, cost shock

Ocugen reported remarkable revenue of $1.53 million in the first quarter—more than three times analysts’ expectations of around $500,000. Despite this, the stock price plummeted nearly 18% in pre-market trading. The reason: Operating expenses climbed to $19.4 million, an increase of over 21% compared to the same period last year. The loss per share was $0.06, missing expectations of $0.05.

The most important event of the week is the placement of convertible bonds totaling $115 million, which is expected to close today. After repaying existing debt, liquidity should increase to approximately $112 million, securing financing until 2028. Without this step, the pipeline would be virtually impossible to finance.

The clinical roadmap is tightly scheduled:

OCU400 (inherited retinal dystrophy): Rolling BLA submission planned from the third quarter of 2026, Phase III topline data in the first quarter of 2027

OCU410ST (Stargardt disease): Recruitment of the Phase II/III GARDian3 trial with 63 participants completed – ahead of schedule. Interim analysis in Q3 2026.

The biotech stock is trading at €1.21, around 17% below its level a week ago. An RSI of 36 indicates oversold territory. The market is currently reacting more strongly to cost developments than to pipeline progress.

Sangamo Therapeutics: From the Nasdaq to the OTC market

The most dramatic chapter of the week is being written by the biotech company Sangamo Therapeutics. Since May 5th, its shares have no longer been traded on the Nasdaq, but on the OTCQB Venture Market. The company had failed to regain the minimum price of $1.00 per share despite two extension deadlines.

The consequences of such a delisting are significant: reduced liquidity, wider bid-ask spreads, and less institutional attention. Despite this, the biotech stock jumped 31.5% to $0.1776 on the day of the announcement—with a trading volume ten times the daily average. Speculative buying in anticipation of strategic deals drives such price swings.

Sangamo states that it is reviewing all strategic options—partnerships, capital increases, and asset sales. Collaborations with Pfizer, Sanofi, Novartis, and Biogen remain in place and provide at least some validation of the technology platform. Analysts are divided: one buy rating is opposed by two sell recommendations, with a consensus price target of $5.50. Given a market capitalization of only around $75 million, the biotech company is a takeover or failure candidate—an interim solution seems unlikely.

Newron SpA: FDA ban slows down schizophrenia study

The Italian biotech company Newron is facing a critical situation. The US Food and Drug Administration (FDA) has halted enrollment of new patients at US sites for its Phase III ENIGMA-TRS 2 trial. This follows the sudden death of a study participant at a site outside the US. The principal investigator determined that the incident was unrelated to the study medication.

Evenamide, a novel glutamate modulator, would, if successful, be the first approved add-on therapy for treatment-resistant schizophrenia. The ENIGMA program includes at least 1,000 patients, and topline results are still expected in the fourth quarter of 2026. In Japan, partner EA Pharma (an Eisai subsidiary) launched its own Phase III trial with Evenamide in January 2026—an additional data catalyst.

Biotech company Newron has secured its finances: €38 million in fresh capital and an extended EIB loan until 2028 go beyond the pivotal data analysis. With a market capitalization of around 338 million Swiss francs, the current share price of €15.25 reflects a significant premium for a single, binary study success. Since the beginning of the year, the biotech stock has lost approximately 43% of its value—the market is demanding results.

Bionxt Solutions: Psychedelics as a new playing field

Bionxt Solutions, listed on the Canadian Securities Exchange (CSE), pursues a dual strategy. Its core program remains the sublingual cladribine thin-film formulation for multiple sclerosis, for which GMP manufacturing was recently completed. A European patent for the oral film technology, valid in up to 39 countries, was granted in March 2026.

In parallel, since the end of April, the biotech company has been exploring the use of its drug delivery technology in the field of psychedelic therapeutics. This is prompted by regulatory relaxations in the US for research on psilocybin and related substances for depression, PTSD, and addiction. Bionxt states that it possesses a proprietary library of psychedelic-inspired compounds.

The biotech stock is trading near its 52-week low of €0.28. A price-to-sales ratio of over 4,000 reflects its status as a development company without significant revenue. Only concrete licensing or partnership agreements would provide a catalyst for the share price – these are currently pending.

The biotech sector between capital stress and catalysts

The next few weeks will bring clarity on several fronts in the biotech sector. For Ocugen, the completion of the convertible bond issue shifts the focus to BLA preparations starting in the third quarter. Redcare needs to demonstrate whether its EBITDA improvement can be sustained in competition with dm and Rossmann. Time is running out for Sangamo—a partner deal or a capital increase is needed soon, otherwise the going concern risk will continue to grow.

Newron’s fourth quarter will be pivotal: If Evenamide delivers positive data, the stock could experience a massive revaluation. If it fails to deliver, the entire investment thesis collapses. Bionxt, on the other hand, needs one thing above all else—a partner willing to bring its technology platform to market. Until then, the stock remains a bet on the future of sublingual drug delivery.

__

(Featured image by Absolut Vision via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in boerse-express. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.